KALAMAZOO, Michigan, USA, March 2, 2023 /PRNewswire/ -- Stryker (NYSE:SYK) announced the launch of its CD NXT System, the latest innovation in the company's power tools. This patented technology provides real-time depth measurement as the surgeon drills, allowing for fast, accurate, consistent digital depth measurement across various procedures.
CD NXT streamlines instrumentation and surgical steps, offering an accurate and reproducible measurement while removing errors commonly associated with a manual depth gauge. The system works independently of the implant system, allowing broad use across the market.
"We continuously listen to the needs and pain points of our customers. We discovered the need for a more accurate and dependable depth measurement tool through research. CD NXT fills that gap through a revolutionary technology allowing the power tool to communicate information back to the surgeon, enabling real-time decision-making," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business.
CD NXT features include:
For more information, including videos, please visit Stryker's CD NXT System product page at https://www.stryker.com//us/en/orthopaedic-instruments/products/cd-nxt.html
About Stryker
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Sr. Director, Strategic Communications
Instruments
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$369.59 |
| Daily Change: | -6.34 -1.69 |
| Daily Volume: | 1,420,549 |
| Market Cap: | US$141.300B |
October 14, 2025 September 09, 2025 July 31, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
